

EyeSense Attracts Lee's Pharmaceutical Holdings as Strategic Investor

Strategic partnership to develop and commercialize a novel continuous blood glucose monitoring system for diabetes patients

Basel, Switzerland/Hong Kong, 27th November 2014 --- EyeSense AG ("EyeSense"), a leading developer of novel continuous blood glucose monitoring systems for diabetes patients, today announced that it has entered into a strategic partnership with Lee's Pharmaceutical Holdings Limited ("Lee's PHARM" - Hong Kong Stock Exchange; Stock Code 950). By combining Lee's PHARM's strong presence in the dynamically growing Chinese and South Asian markets and Eyesense's unique glucose sensing technology, the partners agreed to develop and commercialize a new continuous blood glucose monitoring system for diabetes patients. Lee's PHARM acquired a minority equity stake in EyeSense and Powder Pharmaceuticals Inc., ("Powder"), an associated company of Lee's PHARM, attained rights for the development and future commercialization of the device in China and other South Asian countries, except for Japan. The partnership and investment will allow an expansion of the availability of innovative continuous blood glucose monitoring systems to further improve and individualize the treatment of the steadily growing number of diabetes patients. The financing was led by Rosetta Capital and supported by existing Eyesense investors LSP and BioMedInvest. Financial details of the transaction were not disclosed.

EyeSense's continuous blood glucose monitoring (CGM) approach sets an important milestone in the diabetes field. The Company's innovative and highly accurate device is based on a novel optical sensing technology and initial patient studies have yielded very promising data. Accuracy, reliability, and extended lifetime of the device will enable patients to significantly improve their disease management at reduced costs and high comfort. EyeSense's technology has the potential to grow the CGM market significantly and to allow CGM availability for a large portion of the diabetes population. The company intends to launch the new device in 2016.

"The collaboration with Lee's PHARM and Powder is an important validation of EyeSense's progress to date and substantially strengthens our development and commercialization efforts," said Achim Müller, CEO and co-founder of EyeSense AG. "With its leadership position in the Chinese and South Asian markets, Lee's PHARM and Powder are ideal partners to help us maximize our development and engineering know-how and put our advanced blood glucose monitoring device in the hands of patients in the highly dynamic Chinese market at an accelerated pace."

"Lee's PHARM is investing strategically in innovative companies like EyeSense by taking a minority equity position and partnering to bring novel technologies to market," said Dr. Benjamin Li, CEO for Lee's PHARM. "EyeSense has created a highly innovative product concept with potential to provide significant health benefits to people with diabetes and eliminate the need for painful blood sampling multiple times a day. This partnership adds a promising new, advanced candidate to Lee's PHARM's Group portfolio."

With more than 360 million diabetics in the world today, blood glucose measurement is one of the largest diagnostic markets, generating annual sales estimated at US\$11 billion. Continuous blood glucose monitoring is one of the most effective strategies to prevent serious harm to the patient's health such as cardiovascular disease, kidney failure or blindness. If used regularly with appropriate accuracy, the monitoring of glucose levels can help save health insurance systems billions of dollars, while simultaneously significantly improving patients' health and quality of life.

About EyeSense AG:

EyeSense™ AG is a venture-backed diagnostic device company based in Basel, Switzerland, and with operations near Frankfurt am Main, Germany. EyeSense was founded in 2006 as a spinout from Ciba Vision AG (a Novartis company), and develops diagnostic systems focusing on glucose testing for diabetic patients. In addition to glucose, the testing platform being developed by EyeSense has the potential to measure a broad variety of medical-relevant analytes in patients. See www.eyesense.com for more details.

About Lee's Pharmaceutical Holdings Limited:

Lee's PHARM is a research-based Hong Kong biopharmaceutical company listed in Hong Kong with over 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's PHARM focuses on several key disease areas such as cardiovascular, oncology, gynecology, urology, dermatology and ophthalmology. Lee's PHARM development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's PHARM is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Additional information about Lee's PHARM is available at www.leespharm.com.

About Powder Pharmaceuticals, Incorporated:

Powder is an associated company of Lee's Pharmaceutical Holdings Limited based in Hong Kong. Powder has successfully obtained approval from the U.S. FDA in July 2013 for its manufacturing facilities located in Hong Kong to manufacture the pharmaceutical product/device Zingo® and currently markets the product in the U.S. Powder intends to supply Zingo® globally through international business partners. Furthermore, Powder is developing products that utilize a proprietary needleless, painless, powder delivery technology as well as other medical devices.

For more information:

Achim Müller, CEO
EyeSense AG
Tel.: +49 6026 942 - 121 or 131
e-mail: achim.mueller@eyesense.com

Vivian Fung
Lee's Pharmaceutical Holdings Limited
Tel.: +852 2314 1282
vivian@leespharm.com